Long‐term efficacy and toxicity of bevacizumab‐based therapy in children with recurrent low‐grade gliomas

• DOI: 10.1002/pbc.24297
• Publication Date: 2012-09-13T16:26:45Z
• Authors: Eugene I. Hwang; Regina I. Jakacki; Michael J. Fisher; Lindsay B. Kilburn; Marianna Horn; Gilbert Vezina; Brian R. Rood; Roger J. Packer
• Keywords: Male; Brain Neoplasms; Infant; Angiogenesis Inhibitors; Glioma; Antibodies, Monoclonal, Humanized; 3. Good health; Bevacizumab; 03 medical and health sciences; Treatment Outcome; 0302 clinical medicine; Child, Preschool; Humans; Female; Neoplasm Recurrence, Local; Child; Retrospective Studies

Because definitive resection or radiotherapy for pediatric low-grade gliomas (LGGs) may be associated with severe and permanent adverse effects, medical management has taken a significant role. Bevacizumab-based therapy demonstrated encouraging responses; however, longer-term toxicity, response durability alternative dosing regimens have not been evaluated.This was retrospective review of children multiply recurrent, progressive LGGs treated bevacizumab-based followed at least 12 months after treatment completion. Toxicity uniformly graded imaging centrally reviewed.All fourteen patients had failed two prior regimens; six dissemination. Patients received initial median age 5.3 years (range, 1-12 years). Median duration 1-24 months). an objective response; 2 stable disease. time to maximum 9 weeks 7-17 weeks). No progressed on therapy, although 13/14 stopping bevacizumab 5 months. Four were re-treated all again responded stabilized. Alternative strategies effective, including monotherapy prolonging the interval 3 weeks. High-grade bevacizumab-related toxicities consisted grade proteinuria (n = 2), primary inflammatory arthritis 1), somnolence 1). Toxicities resolved within 6 cessation except one case hypertension.Bevacizumab-based is successful inducing rapid LGG response. progressing off-therapy successfully bevacizumab. Nearly tumors progress once discontinued. are insignificant but usually reversible.